Company profile: Maverick Therapeutics
1.1 - Company Overview
Company description
- Provider of T cell immunotherapies for solid tumor cancers, developing breakthrough treatments with improved safety and efficacy via COBRA, the most advanced bispecific T cell engaging platform in its class designed to safely target solid tumors.
Products and services
- Oncology: Develops custom-engineered COBRA bispecific T cell engaging platform that harnesses the immune system, enhances tumor recognition, and safely targets solid tumors with improved safety and efficacy
- Plasma-Derived Therapies: Produces clinical-grade therapeutics by investing in research and development to generate treatments derived from plasma, translating plasma-based components into accessible medical products
- Rare Genetics & Hematology: Advances targeted programs for rare genetic and hematological conditions to critical development milestones, progressing therapies focused on rare blood and genetic indications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Maverick Therapeutics
Protein Sciences
HQ: United States
Website
- Description: Provider of vaccine and biopharmaceutical research and development for the prevention and treatment of a variety of diseases, leveraging proprietary BEVS protein expression technology to produce high-quality recombinant proteins quickly, reliably, and at low cost; founded in 1983 with over 30 years of experience creating vaccines and other protective medicines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Protein Sciences company profile →
RhoVac
HQ: Denmark
Website
- Description: Provider of an immuno-oncology therapeutic cancer vaccine targeting metastatic cancer cells by recognizing RhoC-overexpressing cells to stimulate an immune response (RV001, in clinical trials), plus oncology technologies: iCIP (LiPlaCis + DRP to identify cisplatin responders and deliver the drug with higher efficacy and less toxicity), LiPlaCis (liposomal cisplatin), and DRP (mRNA-based predictor of cisplatin response).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RhoVac company profile →
Novavax
HQ: United States
Website
- Description: Provider of vaccines and vaccine technologies for infectious diseases, including a recombinant nanoparticle COVID-19 vaccine with Matrix-M adjuvant; a Phase 2 COVID-influenza combination (CIC) vaccine; and the authorized R21/Matrix-M malaria vaccine. Also offers Matrix-M, a saponin-based adjuvant, and recombinant nanoparticle vaccine technology using engineered proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novavax company profile →
Immune Design
HQ: United States
Website
- Description: Provider of vaccines and therapeutics for the prevention and treatment of infectious diseases, leveraging breakthrough technology and dedicated research to better understand the immune system and develop next-generation immune-based solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immune Design company profile →
Exacis
HQ: United States
Website
- Description: Provider of development-stage immuno-oncology solutions, using mRNA-based cell reprogramming to create iPSC and mRNA-based gene editing to engineer iPSC, creating engineered NK and T cells designed to resist host immune rejection to harness the human immune system against cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exacis company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Maverick Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Maverick Therapeutics
2.2 - Growth funds investing in similar companies to Maverick Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Maverick Therapeutics
4.2 - Public trading comparable groups for Maverick Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →